Trial Profile
Use of Omalizumab will increase the pregnancy rate, proof of concept study, where women with asthma and infertility will be treated three times with weight and IgE balanced dosis at the first day of their period bleeding
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 13 Jan 2024
Price :
$35
*
At a glance
- Drugs Omalizumab (Primary)
- Indications Asthma
- Focus Pharmacodynamics; Proof of concept
- Acronyms PRO_ART
- 08 Jan 2024 Planned End Date changed from 31 Dec 2024 to 31 Dec 2029.
- 08 Jan 2024 Status changed from recruiting to active, no longer recruiting.
- 16 Dec 2021 Planned End Date changed from 1 Apr 2021 to 31 Dec 2024.